Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris®) in Patients with Refractory Generalized Myasthenia Gravis (gMG)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Oppenheimer Cuts Price Target on Alexion Pharma (ALXN) Following Data Release
June 7, 2016 9:46 AM EDTOppenheimer maintained an Outperform rating on Alexion Pharmaceuticals (NASDAQ: ALXN), and cut the price target to $221.00 (from $228.00), following the company's announced top-line data from Phase 3 REGAIN study of eculizumab (Soliris) in refractory generalized myasthenia gravis (rGMG).
Analyst Christopher Marai commented, "Alexion announced... More
Alexion Pharma (ALXN): MG P3 Miss Increases Importance of ALXN-1210; PT to $160 - BMO
June 7, 2016 6:18 AM EDTBMO Capital analyst, Ian Somaiya, cut his price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $160 from $168 following disappointing data from the Phase III trial of Soliris in Myasthenia Gravis (MG). Although the totality of the data suggests significant benefit, the study missed its primary endpoint... More
Alexion Pharma (ALXN) Sinks 9% as Trading Resumes
June 6, 2016 4:35 PM EDTAlexion Pharma (NASDAQ: ALXN) has resumed trading and is down 8.9% after Phase 3 REGAIN study of Eculizumab did not reach statistical significance.
... MoreAlexion Pharma (ALXN) to Resume Trading at 4:30PM Following Trial Failure
June 6, 2016 4:14 PM EDTAlexion Pharma (NASDAQ: ALXN) to resume trading at 4:30PM ET after Phase 3 REGAIN Study of Eculizumab did not reach statistical significance.
... More